INTRODUCTION
The optimal management of psoriatic arthritis (PsA) entails the adequate suppression of aberrant inflammatory processes that give rise to the clinical PsA phenotype of joint stiffness, pain, tenderness, and swelling. Categorized as one of the seronegative spondyloarthropathies, PsA can manifest as enthesitis, dactylitis, synovitis, arthritis, and/or axial inflammation, either in isolation or in any combination, although animal models and clinical studies suggest that enthesitis may be the primary lesion [1, 2] . The magnitude and chronicity of psoriatic joint disease and the consequential physical and financial burden, has, in recent years, prioritized PsA on the research agenda [3] .
Compared to rheumatoid arthritis (RA), the optimal management of PsA still lags behind considerably. Prior to the advent of biological therapy for RA, disease-modifying antirheumatic drugs (DMARDs; methotrexate or sulfasalazine), were most well established option, initially as monotherapy and then in combination as required. The superior efficacy of the biological agents, often anchored to methotrexate therapy, are well established in preventing joint damage and minimizing longterm disability in RA [4] [5] [6] .
However, for a number of reasons, making progress in the therapeutic field for PsA has been more complicated. Historically, PsA was viewed as a less prevalent or severe disease. In addition, it is considerably more heterogeneous in its evolution and manifestations compared to RA. To date, a reliable serum biomarker, such as the anti-citrullinated protein antibody in RA, does not exist for psoriatic joint disease detection, and this is likely to have negatively impacted on the generation of good-quality, robust clinical trials for PsA. Whilst conventional DMARDs have been employed as the mainstay of PsA therapy for decades, there is a surprising paucity of data to support their clinical efficacy, with clinical experience generally taking precedence over hard evidence. In addition, the majority of trials in PsA have focused on the treatment of peripheral arthritis in polyarticular disease [7] , and have largely ignored those patients with primarily axial disease and other subgroups including oligoarthritis.
The current British Society of Rheumatology guidelines for the treatment of PsA were published in 2005, when anti-TNF therapy was not widely available [8] . Only one TNF inhibitor was licensed for active PsA in the UK at the time of publication (etanercept), and only one other anti-TNF therapy demonstrated evidence in PsA (infliximab). There are now four TNF inhibitors with proven efficacy in PsA, established by large, good-quality clinical trials, and a number of novel compounds in development which if prove to be safe, may translate into promising additions to the biological armamentarium against PsA [9] [10] [11] [12] [13] . This article assimilates all of the relevant data concerning both old and new biologic molecules, and provides an evidence-based review of the current and emerging therapeutic options for PsA. However, rather than systematically describe and appraise each clinical study in detail, the pertinent commonalities shall be summarized, and relevant differences highlighted. At the current time, patients within the UK must of course fulfill the criteria for biological therapy as stipulated by the National Institute for Health and Clinical Excellence (NICE); that is, they must have failed to improve on or tolerate firstline, disease-modifying agents including methotrexate, leflunomide, and sulfasalazine, either alone or in combination.
ANTI-TNF AGENTS IN PSORIATIC ARTHRITIS
Many pro-inflammatory cytokines have been identified in the pathogenesis of PsA, but amongst these, TNF-alpha exerts a key proinflammatory role [14] . Increased levels of TNFalpha have been observed in skin, synovial fluid, and synovial tissue from patients with PsA [15] and allelic polymorphisms in the promoter region for TNF-alpha have been shown to correlate with certain aspects of the disease [16] . TNF inhibitors have demonstrated efficacy in both the skin and joint manifestations of psoriatic disease, as well as preventing radiographic damage [9] [10] [11] [12] [13] 17] . In the UK, four anti-TNF agents are licensed for the treatment of PsA-infliximab, etanercept, adalimumab, and golimumab. A fifth agent, certolizumab, has also shown promising efficacy in clinical trials [18, 19] . All trials encompass PsA as a single entity, with no primary endpoint data reporting results based on the PsA subtype.
Almost universally, PsA studies have sought to recruit patients with a predominantly peripheral distribution of joint disease. However, it is estimated that up to 40% of patients with PsA will develop some disease within the axial skeleton. Again, no specific data evaluating the effects of TNF inhibitors at this site has been forthcoming, and treatment guidance is based entirely upon data extrapolated from studies into other seronegative spondyloarthropathies, particularly ankylosing spondylitis (AS) [20, 21] . In AS, TNF inhibitors are effective at suppressing the clinical and imaging markers of inflammation [22] and it is this effect that confers the likelihood of benefit in axial PsA-the suppression of associated bone formation (ankylosis) in AS has yet to be determined [23] . Area Severity Index (PASI) response [9] [10] [11] [12] [13] [27] [28] [29] . Of note, the onset of clinical benefit of the TNF receptor construct on etanercept has been reported to be of slower onset in those with more extensive skin disease than for the monoclonal antibodies [9] , although this was challenged by the outcomes of the more recent PRESTA trial [30] . Again, there are no direct head-to-head comparisons available. This slower onset of action is unlikely to pose a significant problem in the rheumatologic arena, where many PsA cases have a low PASI score (and therefore less cosmetic urgency to respond rapidly) and where current data leads us to believe that no association between PASI score and joint disease exists [31] .
In addition to clinical features, subjective improvements in the Health Assessment Questionnaire (HAQ) are reported to be greatest with adalimumab [10, 27] and infliximab [11, 12] at 12 weeks, and with adalimumab [10] , etanercept [28] , golimumab [13] and infliximab [12] at 24 weeks, when compared to non-TNF-alpha biologic agents, such as ustekinumab (UST) [32] [34] . The key pathogenic importance of enthesitis and dactylitis in PsA has been established [2, 35, 36] , and the original studies into TNF inhibitors suggested superiority of some agents (infliximab [11, 12] ) over others. In total, seven randomized controlled trials have published data on enthesitis and dactylitis as secondary endpoints [10-13, 27, 32, 37] . In addition to infliximab [11, 12] , golimumab [13] [37] . However, it is worth noting that the PRESTA trial did not include a placebo arm.
The ADEPT trial reported efficacy of adalimumab on enthesitis and dactylitis as secondary endpoints [10] . Whilst the mean changes were greater in the treatment group over placebo [10] and these responses were maintained throughout 2 years of therapy [38] , these changes were not statistically significant at any time point [10, 38] .
These seven trials also include data for the anti-IL-12/23 agent ustekinumab [32] where it is used primarily for PsA, in our experience, a substantial and meaningful improvement in PASI is repeatedly seen, and it our experience that many rheumatologists are confident in prescribing golimumab where treatment for skin disease is a priority in addition to PsA.
It has repeatedly been shown that infliximab has superior outcomes over etanercept and adalimumab in terms of joint, functional status and rapid skin clearance [50] although for this very reason, it is often not chosen first line and is typically reserved for more recalcitrant and severe PsO (PASI [20) . In addition, infliximab is often used second line as a consequence of its less convenient mode of administration (hospital-based infusion). Of adalimumab and etanercept, the data attempting to demonstrate which is superior for skin and joint disease is conflicting, and is rarely statistically significant [50] . As mentioned previously, there are data to suggest that etanercept may be slower to act [9] , and thus adalimumab may be the most logical first-line choice of TNFalpha inhibitor for patients requiring treatment for both PsO and PsA. However, over a prolonged treatment course (as the majority of patients will need), there are no robust data to refute that etanercept will reach equivalence with adalimumab in terms of achieving PASI 75, PASI 90 and ACR 20 [26] ; therefore the urgency to achieve these responses should be tailored to the individual.
There is a greater body of evidence to show that etanercept is not efficacious in those with IBD, both in the induction and maintenance of remission [51, 52] and it no longer features in the most current Cochrane Systematic Review (2008), which does support the use of infliximab, adalimumab, and certolizumab [53] . As the latter is not currently licensed for use in PsA, either adalimumab or infliximab are recommended as treatment for patients with both IBD and PsA. From a practicality perspective, adalimumab may be more convenient, being self-administered at home.
WHAT TO DO WHEN TNF-INHIBITION FAILS
The real world use of anti-TNF agents is associated with good drug retention in the short term. Large scale data from the Danish DANBIO registry showed that increased levels of C-reactive protein (CRP) at baseline were associated with both good treatment responses and can serve as a predictor of longer term drug retention [25] . This may be of clinical value in selecting cases with a greater burden of inflammation, which are most likely to benefit from treatment with TNF-alpha inhibitors.
TNF-inhibition irrevocably provides a powerful clinical benefit in terms of the signs and symptoms of PsA and can halt the progression of erosion at a population level in the small joints [54] . However, there is a paucity of evidence to confirm that these agents retard the progressive, structural changes seen in PsA and the subsequent joint fusion that occurs most perceptibly in the axial skeleton; this suggests that pathways involving cytokines other than TNF are crucial in new bone formation.
Whilst the investigation of many non-anti-TNF molecules often includes patients who have failed TNF-inhibition, it is worth noting that to date, there are no published, completed, randomized controlled trials in PsA that solely include these patients. As such, there is an unmet need to provide conclusive evidence for a clear management strategy for this patient group. Table 2) .
ANTI IL-12/IL-23 IN PSORIATIC ARTHRITIS
The results of a second phase III RCT (PSUMMIT II) were also released at ACR 2012 [58] . PSUMMIT II recruited 312 patients, 180 of whom were TNF-alpha experienced. In this subgroup, significantly higher numbers of patients receiving ustekinumab achieved ACR20 responses at the primary endpoint (week 24) compared with placebo (Table 1) . For all participants, including those who were biologic naive, significantly greater proportions achieved ACR50 at week 24 compared with placebo, although the improvement failed to reach significance for ACR70 ( Table 1 response of 10% in those previously exposed to TNF inhibitors, compared to 62% in those who were biologic naïve [65] . Whilst the numbers in the latter study were small, it will be interesting to see if this observation is However, the former action necessitates close monitoring of the CD4 count to ensure that it does not drop below 250 cells/mm 3 .
Whilst demonstrating efficacy in moderateto-severe PsO, alefacept was rapidly superseded by the TNF inhibitors. However, as for most biologics, no randomized controlled trials have directly compared the efficacy of alefacept with the other agents. In 2008, Brimhall et al. [68] performed a quantitative meta-analysis of available randomized controlled trials of four biologic agents: alefacept, efalizumab (now withdrawn), etanercept, and infliximab. Across all trials, efficacy was measured by achievement of PASI 75 after 10-14 weeks of treatment-the study showed that all agents were efficacious for improving PsO, though alefacept was the least effective of the agents studied [68] . Pooled relative risk of achieving PASI 75 was 4, 7, 12, and 19 for alefacept, efalizumab, etanercept, and infliximab, respectively, compared with placebo. The corresponding numbers needed to treat were 8, 4, 3, and 2. Alefacept is also slower to act than TNF inhibitors for most PsO patients [68] .
Two studies have assessed the role of alefacept in PsA [33, 69] for the two initial groups, respectively. Amongst patients who received alefacept plus MTX in both phases of the study, the proportion achieving ACR50 increased with the additional course of alefacept from 17% to 34%, and achieving ACR70 from 7% to 12% [69] . [75] and in biologic-naïve patients with active RA [76, 77] has generated particular interest and investigation [78] [79] [80] [81] . These data may support the investigation of abatacept in biologic-naïve patients with early inflammatory joint disease who have had an inadequate response to MTX. However, it is worth noting that patients included in these studies were exposed to concomitant corticosteroids [76, 77] .
CD28 Receptor Inhibitors

SMALL MOLECULES IN PSORIATIC ARTHRITIS
In contrast to biologics, which target soluble extracellular cytokine or cellular receptors, small molecule inhibitors target intracellular enzymes within a signaling pathway, e.g., tyrosine kinases. In essence, this can make it more difficult to anticipate their complete biological effects and may cause potential for unintended side effects, as these molecules will often interact with the same enzymes but in non-targeted cells involved other biological processes. However, if this can be overcome, small molecule inhibitors have several advantages over biologic agents in that they can be administered orally, and as synthetic compounds, they are comparatively inexpensive to manufacture.
Protein Kinase C Inhibitors
The protein kinase C (PKC) family consists of 10 isoenzymes and each play key roles in cellular signaling, migration, survival and death [82] .
Most isoforms are ubiquitously expressed, except PKCc and PKCh. PKCc is exclusively found within the brain, whilst high protein levels of PKCh are seen mostly in hematopoietic cells and skeletal muscle [83] .
PKCh (along with PKCb and PKCd) are functionally important for T and B cell signaling [83, 84] . PKCh is central to T-cell activation as it is the only isoenzyme that is selectively translocated to the T-cell/antigenpresenting cell contact site immediately after cell-to-cell interaction [85] . Furthermore, PKCh is essential for IL-2 production, which is required for T-cell proliferation. PKCa in T cells is required for proliferation [86] , in addition to IFNc and IL-17 production. PKCb is a prerequisite for B cell antigen receptor function, and PKCd for the induction of tolerance [87] . Identification of specific PKC isoenzymes in T and B cells has promoted their attractiveness as therapeutic targets for inflammatory and autoimmune diseases [88] .
To date, only one PKC inhibitorsotrastaurin (AEB071)-is in the exploratory phase of drug development for autoimmune diseases [89] . Sotrastaurin has a strong inhibitory activity on three PKC isoformsPKCh, PKCa and PKCb, and weaker activity on PKCd, PKCe, and PKCg, meaning that in addition to T-cell activity, it has inhibitory effects on several other cells [82] . It affects more than 200 kinases, including those important for early T-cell activation such as Lck and ZAP-70. Phase II trial data have shown promising efficacy in PsO and transplant rejection [90] . The proven potent inhibition of IL-17 by sotrastaurin makes this molecule a potential future therapeutic target in PsA [91] .
Janus Kinase Inhibitors
Another family of kinases commanding interest in PsO are the Janus kinases (JAK), of which there are four members-JAK1, JAK2, JAK3, and TYK2 [92] . These enzymes, which are expressed primarily in immune and hematopoietic cell lineages, form part of the signaling apparatus used by receptors for various cytokines and growth factors. When such receptors are engaged by their specific ligands, JAKs phosphorylate and thus activate members of the signal transducer and activator of transcription (STAT) family [93] . There are seven STATs (STAT 1, 2, 3, 4, 5a , 5b, and 6), each with a variety of distinct effects on gene transcription in cells of the immune system that are critical in processes such as lymphocyte differentiation, immune regulation and inflammation [94] .
Members of the JAK family can combine to form homodimers or heterodimers; these unique pairings give rise to the signaling of specific cytokines. For example, IL-12 and IL-23 have been reported to signal through JAK2-TYK2 heterodimers [92] , thus targeting of this pathway would be expected to produce similar therapeutic efficacy to ustekinumab [95] . JAK inhibitors also inhibit signaling from many other cytokines, including IL-17 (which activates multiple JAKs via IL-17R) [96] , IL-20 promising efficacy has been achieved with a compound now known as tofacitinib (CP-690550) in both disorders [99] [100] [101] . First described in 2003, it was initially described as a JAK3 inhibitor that could prevent allograft rejection [102] . However, it is now considered to powerfully inhibit both JAK1 and JAK3
(which can function as signaling heterodimers), and to a much lesser extent, JAK2 [103] . The reported success in phase III trials means that it has recently been licensed for treatment of RA in the US [100] . The response to tofacitinib of coincidental PsO in patients with inflammatory RA provides a logical argument for investigation of efficacy in PsA, and is likely that trial data will soon become available in this domain.
Therapeutic inhibition of more selective JAK inhibitors is under investigation. The most extensively studied is ruxolitinib (INCB28050), a selective JAK1/JAK2 inhibitor that has been investigated primarily in myelofibrosis. Latterly, a topical preparation of ruxolitinib has been developed for use in the treatment of PsO, and in a phase-IIb proof-of-concept study of 29 patients, has been reported to improve mean total lesion scores (approximately 53% reduction) and PGA at the 1 and 1.5% concentrations after 28 days of continuous use [93, 104] . However, no firm conclusions can be drawn from this small study, and the high placebo response rate (32% reduction in mean total lesion scores) may simply reflect improved compliance with a topical regimen during the trial.
In terms of inflammatory arthritis, significant efficacy (as assessed by improvements in clinical, histologic, and radiographic signs of disease), has been achieved in the rat adjuvant arthritis model, with doses of ruxolitinib providing partial and/ or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3 [105] . Diminution of inflammatory Th1 and Th17 associated cytokine mRNA levels were observed in the draining lymph nodes of treated rats. Ruxolitinib was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematological effects [105] . As a result, clinical evaluation of ruxolitinib for RA is currently underway in humans.
Another orally active small molecule undergoing extensive investigation in a number of inflammatory disorders is ASP015K. This molecule selectively targets JAK1/JAK3 and in a 6-week phase-IIa POC study of patients with PsO, ASP015K was well tolerated and demonstrated dose-dependent improvements in PASI change from baseline [106] . ASP015K is currently being investigated in three phaseIIb studies in patients with RA in the United States, Europe and Japan, with no efficacy data released to date. compared to just 6% in the placebo arm [108] .
In a similar phase II study of 204 patients with PsA, a modest but significant improvement in ACR20 was achieved at both 20 mg twice daily and 40 mg once daily doses. A significant difference was not seen in ACR70, with very few patients achieving such a marked improvement in disease activity [109] the target joint, but this was not statistically significant [112] .
Other Molecules in Phase I/II Studies
Several novel agents are in phase I and II trials for a number of inflammatory/immune cell driven disorders, including PsO and RA. Based on experience, for some, it is likely that the natural evolution of investigation for many of these agents will extend to PsA, whilst safety concerns and disappointing efficacy data may halt the progression of others into the clinical domain. Table 3 
